HMMR Potential As a Diagnostic and Prognostic Biomarker of Cancer-speculation Based on a Pan-cancer Analysis

Overview

Journal Front Surg

Specialty General Surgery

Date 2023 Jan 27

PMID 36704516

Authors

Junyi Shang

Xiaoju Zhang

Guangjie Hou

Yong Qi

Affiliations

Soon will be listed here.

Abstract

Background: Although the status of universal upregulation for the Hyaluronan-Mediated Motility Receptor (HMMR) in pan-cancer is still unknown, HMMR is upregulated and associated with poor prognosis for some tumors.

Methods: Exploring HMMR expression in different tumor types using The Cancer Genome Atlas (TCGA) or other public databases for a pan-cancer analysis, exploring the relationship between HMMR and tumor prognosis, and exploring the role of HMMR in tumor immunity.

Results: No matter the pairing or unpairing of data, HMMR expression generally increased compared to corresponding normal tissue. Based on a CCLE study, our results indicated that HMMR is widely expressed in various tumor cells. For most tumor types, high HMMR expression was associated with reduced Overall Survival (OS), Return to Functional Status (RFS), and Platinum Free Interval (PFI). ROC curves indicated that HMMR displays high prediction potential for most tumor types. In pan-cancer, HMMR is correlated with some clinical staging, immune cells, and immune checkpoints for some tumors. The GO/KEGG enrichment analysis results for proteins most closely related to HMMR indicate that the most highly enriched pathways are all related to tumor development.

Conclusions: Our pan-cancer analysis of HMMR suggests that HMMR can be used as a potential diagnostic and prognostic indicator of pan-cancer and that HMMR may be involved in tumor development.

Citing Articles

Integrative Bioinformatics Analysis for Targeting Hub Genes in Hepatocellular Carcinoma Treatment.

Gudivada I, Amajala K Curr Genomics. 2025; 26(1):48-80.

PMID: 39911278 PMC: 11793067. DOI: 10.2174/0113892029308243240709073945.

Hyaluronan-Mediated Motility Receptor (HMMR) Overexpression Is Correlated with Poor Survival in Patients with B-ALL.

Ramirez-Chiquito J, Villegas-Ruiz V, Medina-Vera I, Sanchez-Cruz I, Frias-Soria C, Caballero Palacios M Int J Mol Sci. 2025; 26(2).

PMID: 39859458 PMC: 11766256. DOI: 10.3390/ijms26020744.

Stochastic Modeling of Biophysical Responses to Perturbation.

Chari T, Gorin G, Pachter L bioRxiv. 2024; .

PMID: 39005347 PMC: 11245117. DOI: 10.1101/2024.07.04.602131.

Integrated bulk and single-cell RNA sequencing identifies an aneuploidy-based gene signature to predict sensitivity of lung adenocarcinoma to traditional chemotherapy drugs and patients' prognosis.

Wang X, Chen J, Li C, Liu Y, Chen S, Lv F PeerJ. 2024; 12:e17545.

PMID: 38938612 PMC: 11210463. DOI: 10.7717/peerj.17545.

Bioinformatics Approach to Identify the Pathogenetic Link of Gut Microbiota-Derived Short-Chain Fatty Acids and Ischemic Stroke.

Ding L, Wang J, Qiu S, Ren Z, Li Y, An P Mol Neurobiol. 2024; 61(11):9478-9490.

PMID: 38649659 PMC: 11496340. DOI: 10.1007/s12035-024-04176-7.

References

Amarnath S, Mangus C, Wang J, Wei F, He A, Kapoor V . The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Transl Med. 2011; 3(111):111ra120. PMC: 3235958. DOI: 10.1126/scitranslmed.3003130. View

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

Zhu A, Finn R, Edeline J, Cattan S, Ogasawara S, Palmer D . Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018; 19(7):940-952. DOI: 10.1016/S1470-2045(18)30351-6. View

Chalmers Z, Connelly C, Fabrizio D, Gay L, Ali S, Ennis R . Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017; 9(1):34. PMC: 5395719. DOI: 10.1186/s13073-017-0424-2. View

Lu D, Bai X, Zou Q, Gan Z, Lv Y . Identification of the association between HMMR expression and progression of hepatocellular carcinoma via construction of a co-expression network. Oncol Lett. 2020; 20(3):2645-2654. PMC: 7403633. DOI: 10.3892/ol.2020.11844. View

Zhou Z, Li Y, Hao H, Wang Y, Zhou Z, Wang Z . Screening Hub Genes as Prognostic Biomarkers of Hepatocellular Carcinoma by Bioinformatics Analysis. Cell Transplant. 2019; 28(1_suppl):76S-86S. PMC: 7016461. DOI: 10.1177/0963689719893950. View

Bazzoun D, Adissu H, Wang L, Urazaev A, Tenvooren I, Fostok S . Connexin 43 maintains tissue polarity and regulates mitotic spindle orientation in the breast epithelium. J Cell Sci. 2019; 132(10). PMC: 6550011. DOI: 10.1242/jcs.223313. View

Hardwick C, Hoare K, Owens R, Hohn H, Hook M, Moore D . Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility. J Cell Biol. 1992; 117(6):1343-50. PMC: 2289508. DOI: 10.1083/jcb.117.6.1343. View

Stevens L, Cheung W, Adua S, Arnal-Estape A, Zhao M, Liu Z . Extracellular Matrix Receptor Expression in Subtypes of Lung Adenocarcinoma Potentiates Outgrowth of Micrometastases. Cancer Res. 2017; 77(8):1905-1917. PMC: 5468792. DOI: 10.1158/0008-5472.CAN-16-1978. View

10.

Yeh M, Tzeng Y, Fu T, You J, Chang H, Ger L . Extracellular Matrix-receptor Interaction Signaling Genes Associated with Inferior Breast Cancer Survival. Anticancer Res. 2018; 38(8):4593-4605. DOI: 10.21873/anticanres.12764. View

11.

Aran D, Hu Z, Butte A . xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017; 18(1):220. PMC: 5688663. DOI: 10.1186/s13059-017-1349-1. View

12.

Le D, Durham J, Smith K, Wang H, Bartlett B, Aulakh L . Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017; 357(6349):409-413. PMC: 5576142. DOI: 10.1126/science.aan6733. View

13.

Dominguez D, Tsai Y, Gomez N, Jha D, Davis I, Wang Z . A high-resolution transcriptome map of cell cycle reveals novel connections between periodic genes and cancer. Cell Res. 2016; 26(8):946-62. PMC: 4973334. DOI: 10.1038/cr.2016.84. View

14.

Racle J, de Jonge K, Baumgaertner P, Speiser D, Gfeller D . Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. Elife. 2017; 6. PMC: 5718706. DOI: 10.7554/eLife.26476. View

15.

Ghandi M, Huang F, Jane-Valbuena J, Kryukov G, Lo C, McDonald 3rd E . Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019; 569(7757):503-508. PMC: 6697103. DOI: 10.1038/s41586-019-1186-3. View

16.

Li H, Kroll T, Moll J, Frappart L, Herrlich P, Heuer H . Spindle Misorientation of Cerebral and Cerebellar Progenitors Is a Mechanistic Cause of Megalencephaly. Stem Cell Reports. 2017; 9(4):1071-1080. PMC: 5639290. DOI: 10.1016/j.stemcr.2017.08.013. View

17.

Finotello F, Mayer C, Plattner C, Laschober G, Rieder D, Hackl H . Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Med. 2019; 11(1):34. PMC: 6534875. DOI: 10.1186/s13073-019-0638-6. View

18.

Torre L, Siegel R, Ward E, Jemal A . Global Cancer Incidence and Mortality Rates and Trends--An Update. Cancer Epidemiol Biomarkers Prev. 2015; 25(1):16-27. DOI: 10.1158/1055-9965.EPI-15-0578. View

19.

Liu W, Ma J, Cheng Y, Zhang H, Luo W, Zhang H . HMMR antisense RNA 1, a novel long noncoding RNA, regulates the progression of basal-like breast cancer cells. Breast Cancer (Dove Med Press). 2016; 8:223-229. PMC: 5125767. DOI: 10.2147/BCTT.S119997. View

20.

Bonneville R, Krook M, Kautto E, Miya J, Wing M, Chen H . Landscape of Microsatellite Instability Across 39 Cancer Types. JCO Precis Oncol. 2018; 2017. PMC: 5972025. DOI: 10.1200/PO.17.00073. View